A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies

Trial Information

A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies

Background:

- Gastrointestinal (GI) carcinomas represent one of the most commonly diagnosed
malignancies in the United States.

- A sensitive and specific marker of tumor persistence or recurrence would permit a more
accurate determination of the appropriateness of adjuvant therapy in patients with no
clinical evidence of disease following curative resection and allow the diagnosis of
recurrences at earlier stages that may be amenable to curative salvage therapies.

- A biomarker detectable shortly after treatment or in the early stages of chronic
radiation toxicity may allow the identification of patients at risk and early
intervention.

Objectives:

- Our primary objective is to determine if patient specific tumor markers in stool,
urine, or serum can be reliably detected prior to treatment and followed after
treatment to monitor the extent of residual disease.

- A second objective is to evaluate the predictive value of potential markers of chronic
gastrointestinal injury after radiotherapy.

Eligibility:

- Age greater than or equal to 18 years

- Histologically confirmed carcinoma of the gastrointestinal tract (esophagus, stomach,
pancreas, rectum)

- Planned to receive radiotherapy to the site of the gastrointestinal malignancy on an
NCI protocol

Design:

- This protocol provides a means of acquiring tissue, serum, urine, and stool samples
from patients who will receive radiation therapy as part of their treatment for
gastrointestinal malignancies.

- Patients treated with radiation therapy on NCI treatment protocols will be asked to
provide samples prior to any local or systemic therapy as well as before, during and
after their radiation treatment.

- These samples will be tested for the presence of tumor specific DNA mutations and
aberrant methylation patterns determined to be present in each patient's tumor by
screening of initial biopsy or surgical material.

- Tumor markers specific to each patient, such as tumor specific DNA mutations or
aberrant DNA methylation, may provide an individualized method to evaluate disease
status and determine prognosis after therapy. Additionally, a number of stool and
serum markers will be explored as early indicators of acute and eventual chronic
gastrointestinal injury in patients receiving radiotherapy to the abdomen.